Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Recruiting 228Active not recruiting 154Completed 99Not yet recruiting 56Terminated 30Withdrawn 5Temporarily not available 2Suspended 2Enrolling by invitation 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Lymphoid 1

Conditions

Pancreatic Neoplasms 3Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Borderline Resectable Pancreatic Adenocarcinoma 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 14Specimen Handling 13Cyclophosphamide 11fludarabine 10Radiotherapy 9Biopsy 9atezolizumab 7Nivolumab 7Radiation 6Gemcitabine 5fludarabine phosphate 4aldesleukin 4Prednisone 4Paclitaxel 4Etoposide 4Cytarabine 4Cisplatin 4Carboplatin 4Blood Specimen Collection 4Bevacizumab 4ALT-803 4venetoclax 3lenvatinib 3avelumab 3X-Rays 3Vincristine 3Surveys and Questionnaires 3Rituximab 3Phantoms, Imaging 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Gemcitabine × 1 year × Clear all
NCT05415917 2026-05-07

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06498518 2025-07-11

PRIMUS006

University of Glasgow

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT06592664 2025-06-06

FORTIFIDE

Lisata Therapeutics, Inc.

Phase 1/2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡